New York, Jan 9, 2026, 13:50 EST — Regular session
- Establishment Labs shares slip about 5% in early afternoon trade, giving back some ground after a strong start to the week
- Broader U.S. stocks climb after a softer December jobs report
- Attention now turns to a Jan. 14 J.P. Morgan Healthcare Conference presentation and the FDA review track for Motiva
Establishment Labs Holdings Inc. shares slid about 5% to $69.22 in early afternoon trading Friday, after earlier rising as high as $74.37.
The move stands out because the stock has been among the sharper movers in small-cap medical devices this week, and traders are balancing two timelines: near-term investor events and the longer U.S. regulatory process for its Motiva breast implants.
On Friday, the broader market climbed after U.S. data showed employers added 50,000 jobs in December, leaving rate-cut bets intact even as the unemployment rate ticked down to 4.4%. Establishment Labs, meanwhile, was headed in the opposite direction. Reuters
The company said in late December that Chief Executive Officer Peter Caldini and Chief Financial Officer Raj Denhoy are set to present at the J.P. Morgan Healthcare Conference on Jan. 14, and that a live webcast is planned. investors.establishmentlabs.com
The presentation comes as investors chew over the company’s push into breast reconstruction, after it said it submitted Motiva implants to the U.S. Food and Drug Administration for approval in primary and revision reconstruction. “Expanding our FDA approval from breast augmentation to reconstruction is an important step forward for women’s health,” Jeff Ehrhardt, its North America general manager, said in the release. (Premarket approval is the FDA’s most stringent device review route.) investors.establishmentlabs.com
The stock rose about 10% from Monday’s close to Thursday’s finish, then Friday’s pullback pared back the week’s advance. Establishment Labs’ investor site lists the shares at $72.92 at Thursday’s close, up from $66.43 on Monday. investors.establishmentlabs.com
But the path ahead isn’t clean. The FDA could ask for more data or simply take longer than investors expect, and pricing pressure remains a constant risk in a market dominated by entrenched players like Allergan Aesthetics (an AbbVie unit) and Johnson & Johnson’s Mentor franchise. natrelle.com
Establishment Labs manufactures and sells medical devices for aesthetic and reconstructive plastic surgery, including breast implants. Yahoo Finance
Next, investors will be listening for any updates at the Jan. 14 conference, before shifting focus to the company’s next results, which Nasdaq’s earnings calendar pegs for Feb. 25. Nasdaq
